750 Corporate Drive
106 articles with Glenmark Pharmaceuticals
7/27/2020It was a busy week for clinical trial news, with some very important early-stage trial data for various COVID-19 vaccines. Here’s a look.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 24, 2020.
An antiviral drug developed by Glenmark Pharmaceuticals boosted the time it takes COVID-19 patients with mild to moderate symptoms to improve their health in a Phase III study.
7/2/2020Biopharma and life sciences companies provide updates on their pipelines and business plans.
The U.S. Justice Department charged Glenmark Pharmaceuticals, headquartered in India, with conspiring with other generic drug companies to increase and hold prices for the cholesterol drug pravastatin between May 2013 and December 2015.
Glenmark Becomes the First Pharmaceutical Company in India to Receive Regulatory Approval for Oral Antiviral Favipiravir, for the Treatment of Mild to Moderate COVID-19
Manufacturing and marketing approval granted as part of accelerated approval process, considering the emergency situation of the COVID-19 outbreak in India
Glenmark to Commence New Phase 3 Clinical Trial on Combination of Two Anti-viral Drugs Favipiravir and Umifenovir in Hospitalized Patients of Moderate COVID-19 in India
Glenmark Pharmaceuticals, a global pharmaceutical company, announced a new randomized, open-label study to test the combined efficacy of two antiviral drugs Favipiravir and Umifenovir as a potential COVID-19 treatment strategy.
COVID-19 patients from over 10 leading government and private hospitals in India are being enrolled for the study
Following months of concerns regarding the potential contamination of ranitidine-based products with known carcinogens, the U.S. Food and Drug Administration is asking manufacturers to immediately withdraw all prescription and over-the-counter drugs from the market.
Another recall has been issued for ranitidine tablets due to the presence of a carcinogen contaminant.
Horizon Discovery Signs License Agreement With Glenmark Pharmaceuticals for GS Knockout CHO Cell Line for Manufacture of Biotherapeutics
Glenmark signs full commercial-use license for Horizon’s gene-edited CHO cells
Glenmark said it should be able to resolve the FDA's concerns within six to nine weeks and will work with the regulatory agency toward approval.
Glenmark Pharmaceuticals Announces Results from a Phase 3 Study of Ryaltris™, an Investigational Product for the Treatment of Seasonal Allergic Rhinitis, in Patients Aged 6 to Under 12 Years
The study of Ryaltris (olopatadine hydrochloride [665 mcg] and mometasone furoate [25 mcg] nasal spray) in pediatric patients aged 6 to under 12 years of age met its primary endpoint, and results were consistent with extensive clinical trial experience with Ryaltris in patients 12 years of age and older
4/18/2019In the first quarter of 2019, more than 30 life science companies* announced expansions, new locations, increased funding, new trial and product launches and various other news pointing to a growing industry.
3/8/2019Perhaps the biggest mover and shaker announcement this week was the unexpected resignation of Scott Gottlieb, commissioner of the U.S. Food and Drug Administration. Gottlieb will leave his post later this month to spend more time with his family.
Glenmark Pharmaceuticals’ new innovation business has its chief executive officer. Alessandro Riva, head of oncology therapeutics and cell therapy at Gilead Sciences will take over the reins of the new innovation company as its CEO on April 2. Riva is the first named executive of the new company.
Glenmark Pharmaceuticals Announces Appointment of Alessandro Riva as CEO of its New Innovation Company
Glenmark Pharmaceuticals, a research-led, integrated global pharmaceutical company, today announced that Alessandro Riva, MD, will join its new innovation company as Chief Executive Officer.
Glenmark Pharmaceuticals Announces Presentation of New Subtype Analysis of GBR 830, an Investigational, Anti-OX40 Monoclonal Antibody, at the American Academy of Dermatology Annual Meeting
Glenmark Pharmaceuticals, a global pharmaceutical company, today announced the presentation of a new post hoc analysis of data from a Phase 2a, proof-of-concept study of GBR 830 at the American Academy of Dermatology (AAD) Annual Meeting in Washington, DC.
Glenmark Pharmaceuticals Announces Results from New Analysis of Pooled Data on Ryaltris™, an Investigational Product for the Treatment of Seasonal Allergic Rhinitis, at the AAAAI 2019 Annual Meeting
Glenmark Pharmaceuticals, a global innovative pharmaceutical company, today announced results from new analyses of pooled data from clinical studies of Ryaltris
Glenmark Pharmaceuticals to Present New Analysis of Pooled Data on Ryaltris™, an Investigational Product for the Treatment of Seasonal Allergic Rhinitis, at the AAAAI 2019 Annual Meeting
Ryaltris also known as GSP 301 Nasal Spray, is the company's leading respiratory pipeline asset and currently under review with the U.S. Food and Drug Administration as a treatment of seasonal allergic rhinitis in patients 12 years and older